Review on application and development of pharmacogenomics of adverse drug reactions

Abstract

Adverse drug reactions (ADRs) are a significant public health issue, contributing substantially to patient morbidity and mortality. The growing accessibility of genomic technologies has greatly advanced our understanding of the genetics underlying ADRs. Pharmacogenomics, which investigates how genetic polymorphisms influence individual responses to drug therapy on a genome-wide scale, plays a pivotal role in this field. The article summarizes the relationship between ADRs and genes, outlines the current applications and advancements of pharmacogenomics in the prediction, diagnosis, prevention, regulation, and personalized treatment of ADRs, and reviews cutting-edge research methods and large-scale international studies. These insights aim to provide a reference for the future development of pharmacogenomics in ADR research.